The AVPN South Asia Summit in December 2023 brought together social impact thought leaders and industry experts from South Asian countries
Takeda Biopharmaceuticals India (formerly Baxalta Bioscience India) – a global values-based, R&D-driven biopharmaceutical leader – presented an industry perspective on the substantial need for vaccine equity and novel strategies for vector-borne disease financing at the Asian Venture Philanthropy Network (AVPN) South Asia Summit December 2023.
Speaking at the summit, Dr Ruchi Sogarwal, Head of Corporate Affairs, Takeda Biopharmaceuticals India said, “South Asian countries have experienced substantial outbreaks of vector-borne infectious diseases which makes the need for newer prevention modalities including vaccine no longer a choice but a strategic imperative. The formation of cross-sectoral multi-stakeholder alliances is required to deliver a new collaborative model for accelerated R&D, scale-up of vaccine production, leveraging technology for more resilient supply chain networks, and enabling systems for equitable and cost-effective vaccine delivery. Besides that, proactive engagement of civil society organizations is essential to enhance the uptake of such disease prevention modalities across different geographies and epidemiological settings.”
Gopal Agarwal, Head of Market Access and Pricing, Takeda Biopharmaceuticals India, added, “As vector-borne diseases continue to put increasing financial strain on the already stretched healthcare systems of today, innovative financing becomes indispensable. By fostering public-private partnerships and harnessing impact investments, we can reshape the landscape of disease prevention and control to create a healthier future for at-risk populations.”
The AVPN South Asia Summit in December 2023 brought together social impact thought leaders and industry experts from South Asian countries who engaged in decisive dialogues strategically aimed at identifying innovative partnership avenues and steering collective efforts for advancing positive change.
Keywords:
